Cancer - ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Condition or Therapy:
Primary Mediastinal B-Cell Lymphoma
What is the goal of this study?
The goal of this study to see if nivolumab + chemo-immunotherapy works better than chemo-immunotherapy alone. The study will be looking at the rate of remission, the rate of progression/relapse and the efficacy of these drugs.
Who can join the study?
This study may be a good for for children and young adults who are:
- 2 years or older
- Diagnosed with primary mediastinal B-cell lymphoma
You can read more about the eligibility criteria for this study on clinicaltrials.gov.
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for your child.
What will happen if my child takes part in this study?
Participants in this study will:
- Be randomized to an arm of the study
- Take up to six courses of chemotherapy
- Have imaging scans done to assess disease
- Give blood at set timepoints for research studies
Who can I contact for more information?
Please email the research coordinator or call the study team at (206) 987-2106 for more information about this study.